Management of melioidosis

References

• White NJ. Melioidosis. Lancet361, 1715–1722 (2003).
   PubMed Web of Science ®Google Scholar
• Currie BJ, Fisher DA, Howard DM et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis.31, 981–986 (2000).
   PubMed Web of Science ®Google Scholar
• Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev.18, 383–416 (2005).
   PubMed Web of Science ®Google Scholar
• Currie BJ, Jacups SP, Cheng AC et al. Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Trop. Med. Int. Health9, 1167–1174 (2004).
   PubMed Web of Science ®Google Scholar
• Puthucheary SD, Parasakthi N, Lee MK. Septicaemic melioidosis: a review of 50 cases from Malaysia. Trans. R Soc. Trop. Med. Hyg.86, 683–685 (1992).
   PubMed Web of Science ®Google Scholar
• Suputtamongkol Y, Chaowagul W, Chetchotisakd P et al. Risk factors for melioidosis and bacteremic melioidosis. Clin. Infect. Dis.29, 408–413 (1999).
   PubMed Web of Science ®Google Scholar
• Currie BJ, Fisher DA, Howard DM et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop.74, 121–127 (2000).
   PubMed Web of Science ®Google Scholar
• Chierakul W, Winothai W, Wattanawaitunechai C et al. Melioidosis in 6 tsunami survivors in southern Thailand. Clin. Infect. Dis.41, 982–990 (2005).
   PubMed Web of Science ®Google Scholar
• Mays EE, Ricketts EA. Melioidosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest68, 261–263 (1975).
   PubMed Web of Science ®Google Scholar
• Chodimella U, Hoppes WL, Whalen S, Ognibene AJ, Rutecki GW. Septicemia and suppuration in a Vietnam veteran. Hosp. Pract.32, 219–221 (1997).
   Web of Science ®Google Scholar
• Ngauy V, Lemeshev Y, Sadkowski L, Crawford G. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J. Clin. Microbiol.43, 970–972 (2005).
   PubMed Web of Science ®Google Scholar
• Chadwick DR, Ang B, Sitoh YY, Lee CC. Cerebral melioidosis in Singapore: a review of five cases. Trans. R Soc. Trop. Med. Hyg.96, 72–76 (2002).
   PubMed Web of Science ®Google Scholar
• Dance DA, Davis TM, Wattanagoon Y et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J. Infect. Dis.159, 654–660 (1989).
   PubMed Web of Science ®Google Scholar
• Tiangpitayakorn C, Songsivilai S, Piyasangthong N, Dharakul T. Speed of detection of Burkholderia pseudomallei in blood cultures and its correlation with the clinical outcome. Am. J. Trop. Med. Hyg.57, 96–99 (1997).
   PubMed Web of Science ®Google Scholar
• Walsh AL, Smith MD, Wuthiekanun V et al. Prognostic significance of quantitative bacteremia in septicemic melioidosis. Clin. Infect. Dis.21, 1498–500 (1995).
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Wuthiekanun V, Chierakul W et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J. Clin. Microbiol.43, 2274–2276 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng AC, Jacups SP, Anstey NM, Currie BJ. A proposed scoring system for predicting mortality in melioidosis. Trans. R Soc. Trop. Med. Hyg.97, 577–581 (2003).
   PubMed Web of Science ®Google Scholar
• Ashdown LR. Serial serum C-reactive protein levels as an aid to the management of melioidosis. Am. J. Trop. Med. Hyg.46, 151–157 (1992).
   PubMed Web of Science ®Google Scholar
• Cheng AC, Obrien M, Jacups SP, Anstey NM, Currie BJ. C-reactive protein in the diagnosis of melioidosis. Am. J. Trop. Med. Hyg.70, 580–582 (2004).
   PubMed Web of Science ®Google Scholar
• Reechaipichitkul W. Clinical manifestation of pulmonary melioidosis in adults. Southeast Asian J. Trop. Med. Public Health35, 664–669 (2004).
   PubMedGoogle Scholar
• Aphinives C, Pacheerat K, Chaiyakum J, Laopaiboon V, Aphinives P, Phuttharak W. Prostatic abscesses: radiographic findings and treatment. J. Med. Assoc. Thai.87, 810–815 (2004).
   PubMedGoogle Scholar
• Abbink FC, Orendi JM, de Beaufort AJ. Mother-to-child transmission of Burkholderia pseudomallei. N. Engl. J. Med.344, 1171–1172 (2001).
   PubMedGoogle Scholar
• Ralph A, McBride J, Currie BJ. Transmission of Burkholderia pseudomallei via breast milk in northern Australia. Pediatr. Infect. Dis. J.23, 1169–1171 (2004).
   PubMed Web of Science ®Google Scholar
• McCormick JB, Sexton DJ, McMurray JG, Carey E, Hayes P, Feldman RA. Human-to-human transmission of Pseudomonas pseudomallei. Ann. Intern. Med.83, 512–513 (1975).
   PubMed Web of Science ®Google Scholar
• Kunakorn M, Jayanetra P, Tanphaichitra D. Man-to-man transmission of melioidosis. Lancet337, 1290–1291 (1991).
   PubMedGoogle Scholar
• Holland DJ, Wesley A, Drinkovic D, Currie BJ. Cystic fibrosis and Burkholderia pseudomallei infection: an emerging problem? Clin. Infect. Dis.35, e138–e140 (2002).
   PubMed Web of Science ®Google Scholar
• Ashdown LR. Nosocomial infection due to Pseudomonas pseudomallei: two cases and an epidemiologic study. Rev. Infect. Dis.1, 891–894 (1979).
   PubMedGoogle Scholar
• Ashdown LR. In vitro activities of the newer β-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei. Antimicrob. Agents Chemother.32, 1435–1436 (1988).
   PubMed Web of Science ®Google Scholar
• Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J. Antimicrob. Chemother.54, 1134–1138 (2004).
   PubMed Web of Science ®Google Scholar
• McEniry DW, Gillespie SH, Felmingham D. Susceptibility of Pseudomonas pseudomallei to new β-lactam and aminoglycoside antibiotics. J. Antimicrob. Chemother.21, 171–175 (1988).
   PubMed Web of Science ®Google Scholar
• Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbapenem antibiotics against β-lactam susceptible and resistant strains of Burkholderia pseudomallei. J. Antimicrob. Chemother.37, 611–615 (1996).
   PubMed Web of Science ®Google Scholar
• Dance DA, Wuthiekanun V, Chaowagul W, White NJ. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother.24, 295–309 (1989).
   PubMed Web of Science ®Google Scholar
• Winton MD, Everett ED, Dolan SA. Activities of five new fluoroquinolones against Pseudomonas pseudomallei. Antimicrob. Agents Chemother.32, 928–929 (1988).
   PubMed Web of Science ®Google Scholar
• Ho PL, Cheung TK, Kinoshita R, Tse CW, Yuen KY, Chau PY. Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother.49, 1042–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Simpson AJ, White NJ, Wuthiekanun V. Aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother.43, 2332 (1999).
   PubMed Web of Science ®Google Scholar
• Walsh AL, Smith MD, Wuthiekanun V, White NJ. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment. Antimicrob. Agents Chemother.39, 2356–2358 (1995).
   PubMed Web of Science ®Google Scholar
• Lumbiganon P, Tattawasatra U, Chetchotisakd P, Wongratanacheewin S, Thinkhamrop B. Comparison between the antimicrobial susceptibility of Burkholderia pseudomallei to trimethoprim–sulfamethoxazole by standard disk diffusion method and by minimal inhibitory concentration determination. J. Med. Assoc. Thai.83, 856–860 (2000).
   PubMedGoogle Scholar
• Piliouras P, Ulett GC, Ashhurst-Smith C, Hirst RG, Norton RE. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int. J. Antimicrob. Agents19, 427–429 (2002).
   PubMed Web of Science ®Google Scholar
• Wuthiekanun V, Cheng AC, Chierakul W et al. Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother.55, 1029–1031 (2005).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Chau PY, Wong AI, Leung YK. β-lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance. J. Antimicrob. Chemother.20, 313–321 (1987).
   PubMed Web of Science ®Google Scholar
• Cheung TK, Ho PL, Woo PC, Yuen KY, Chau PY. Cloning and expression of class A β-lactamase gene blaA (BPS) in Burkholderia pseudomallei. Antimicrob. Agents Chemother.46, 1132–1135 (2002).
   PubMed Web of Science ®Google Scholar
• Niumsup P, Wuthiekanun V. Cloning of the class D β-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J. Antimicrob. Chemother.50, 445–455 (2002).
   PubMed Web of Science ®Google Scholar
• Godfrey AJ, Wong S, Dance DA, Chaowagul W, Bryan LE. Pseudomonas pseudomallei resistance to β-lactam antibiotics due to alterations in the chromosomally encoded β-lactamase. Antimicrob. Agents Chemother.35, 1635–1640 (1991).
   PubMed Web of Science ®Google Scholar
• Tribuddharat C, Moore RA, Baker P, Woods DE. Burkholderia pseudomallei class A β-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother.47, 2082–2087 (2003).
   PubMed Web of Science ®Google Scholar
• Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother.43, 465–470 (1999).
   PubMed Web of Science ®Google Scholar
• Chan YY, Tan TM, Ong YM, Chua KL. BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob. Agents Chemother.48, 1128–1135 (2004).
   PubMed Web of Science ®Google Scholar
• Chan YY, Chua KL. The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J. Bacteriol.187, 4707–4719 (2005).
   PubMed Web of Science ®Google Scholar
• Burtnick MN, Woods DE. Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance. Antimicrob. Agents Chemother.43, 2648–2656 (1999).
   PubMed Web of Science ®Google Scholar
• Holden MT, Titball RW, Peacock SJ et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl Acad. Sci. USA101, 14240–14245 (2004).
   PubMed Web of Science ®Google Scholar
• Jenney AW, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int. J. Antimicrob. Agents17, 109–113 (2001).
   PubMed Web of Science ®Google Scholar
• Chen K, Sun GW, Chua KL, Gan YH. Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments. Antimicrob. Agents Chemother.49, 1002–1009 (2005).
   PubMed Web of Science ®Google Scholar
• Haussler S, Rohde M, Steinmetz I. Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis. Med. Microbiol. Immunol. (Berl.)188, 91–97 (1999).
   PubMed Web of Science ®Google Scholar
• Vorachit M, Lam K, Jayanetra P, Costerton JW. Resistance of Pseudomonas pseudomallei growing as a biofilm on silastic discs to ceftazidime and co-trimoxazole. Antimicrob. Agents Chemother.37, 2000–2002 (1993).
   PubMed Web of Science ®Google Scholar
• Russell P, Eley SM, Ellis J et al. Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J. Antimicrob. Chemother.45, 813–818 (2000).
   PubMed Web of Science ®Google Scholar
• Ulett GC, Norton RE, Hirst RG. Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model. Pathology31, 264–267 (1999).
   PubMed Web of Science ®Google Scholar
• Ulett GC, Hirst R, Bowden B, Powell K, Norton R. A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model. J. Antimicrob. Chemother.51, 77–81 (2003).
   PubMed Web of Science ®Google Scholar
• White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet2, 697–701 (1989).
   PubMed Web of Science ®Google Scholar
• Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob. Agents Chemother.36, 158–162 (1992).
   PubMed Web of Science ®Google Scholar
• Thamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbactam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. J. Med. Assoc. Thai.81, 265–271 (1998).
   PubMedGoogle Scholar
• Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin. Infect. Dis.33, 29–34 (2001).
   PubMed Web of Science ®Google Scholar
• Chierakul W, Anunnatsiri S, Short JM et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim–sulfamethoxazole for the treatment of severe melioidosis. Clin. Infect. Dis.41, 1105–1113 (2005).
   PubMed Web of Science ®Google Scholar
• Suputtamongkol Y, Rajchanuwong A, Chaowagul W et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin. Infect. Dis.19, 846–853 (1994).
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Suputtamongkol Y, Smith MD et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis.29, 381–387 (1999).
   PubMed Web of Science ®Google Scholar
• Cheng AC, Fisher DA, Anstey NM, Stephens DP, Jacups SP, Currie BJ. Outcomes of patients with melioidosis treated with meropenem. Antimicrob. Agents Chemother.48, 1763–1765 (2004).
   PubMed Web of Science ®Google Scholar
• Rajchanuvong A, Chaowagul W, Suputtamongkol Y, Smith MD, Dance DA, White NJ. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans. R Soc. Trop. Med. Hyg.89, 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Chaowagul W, Simpson AJ, Suputtamongkol Y, Smith MD, Angus BJ, White NJ. A comparison of chloramphenicol, trimethoprim–sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin. Infect. Dis.29, 375–380 (1999).
   PubMed Web of Science ®Google Scholar
• Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am. J. Trop. Med. Hyg.64, 24–27 (2001).
   PubMedGoogle Scholar
• Chaowagul W, Suputtamongkul Y, Smith MD, White NJ. Oral fluoroquinolones for maintenance treatment of melioidosis. Trans. R Soc. Trop. Med. Hyg.91, 599–601 (1997).
   PubMed Web of Science ®Google Scholar
• Chaowagul W, Chierakul W, Simpson AJ et al. Open-label randomized trial of oral trimethoprim–sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim–sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob. Agents Chemother.49, 4020–4025 (2005).
   PubMed Web of Science ®Google Scholar
• Angus BJ, Smith MD, Suputtamongkol Y et al. Pharmacokinetic–pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br. J. Clin. Pharmacol.50, 184–191 (2000).
   PubMed Web of Science ®Google Scholar
• Huffam S, Jacups SP, Kittler P, Currie BJ. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters. Trop. Med. Int. Health9, 715–717 (2004).
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Dance DA, Wuthiekanun V, White NJ. Serum bactericidal and inhibitory titres in the management of melioidosis. J. Antimicrob. Chemother.45, 123–127 (2000).
   PubMed Web of Science ®Google Scholar
• Soontornpas C, Saraya S, Chulasiri M, Chindavijak B, Mootsikapun P. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis. Int. J. Antimicrob. Agents26, 403–407 (2005).
   PubMed Web of Science ®Google Scholar
• Currie BJ, Fisher DA, Anstey NM, Jacups SP. Melioidosis: acute and chronic disease, relapse and re-activation. Trans. R Soc. Trop. Med. Hyg.94, 301–304 (2000).
   PubMed Web of Science ®Google Scholar
• Maharjan B, Chantratita N, Vesaratchavest M et al. Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse. J. Clin. Microbiol.43, 6032–6034 (2005).
   PubMed Web of Science ®Google Scholar
• Samuel M, Ti TY. Interventions for treating melioidosis. Cochrane Database Syst. Rev.2, CD001263 (2001).
   Google Scholar
• Samuel M, Ti TY. Interventions for treating melioidosis. Cochrane Database Syst. Rev.4, CD001263 (2002).
   Google Scholar
• Currie B. Combination antimicrobial therapy for severe melioidosis. Australian Society for Antimicrobials Newsletter. 23, 16 (2005).
   Google Scholar
• Bossi P, Tegnell A, Baka A et al. Bichat guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro. Surveill.9, E17–E18 (2004).
   PubMedGoogle Scholar
• Cheng AC, Dance DA, Currie BJ. Bioterrorism, glanders and melioidosis. Euro. Surveill.10, E1–E2 (2005).
   Google Scholar
• Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin. Infect. Dis.38, 32–37 (2004).
   PubMed Web of Science ®Google Scholar
• Suputtamongkol Y, Intaranongpai S, Smith MD et al. A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob. Agents Chemother.44, 693–696 (2000).
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S et al.; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med.345, 1368–1377 (2001).
   PubMed Web of Science ®Google Scholar
• van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med.345, 1359–1367 (2001).
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF et al. Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med.344, 699–709 (2001).
   PubMed Web of Science ®Google Scholar